[ CAS No. 755038-02-9 ] {[proInfo.proName]}

Name: 755038-02-9|(R)-4-((8-Cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide|98%
Brand: Ambeed
SKU: A203461
Price: 40.0 USD
Availability: InStock
Rating: 92 (30 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

2D 3D

Structure of 755038-02-9 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 755038-02-9 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 755038-02-9 ]

SDS Specification

Alternatived Products of [ 755038-02-9 ]

Product Details of [ 755038-02-9 ]

CAS No. :	755038-02-9	MDL No. :	MFCD10565924
Formula :	C₂₈H₃₉N₇O₃	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	XQVVPGYIWAGRNI-JOCHJYFZSA-N
M.W :	521.65	Pubchem ID :	11364421
Synonyms :

Calculated chemistry of [ 755038-02-9 ]

Physicochemical Properties

Num. heavy atoms :	38
Num. arom. heavy atoms :	12
Fraction Csp3 :	0.57
Num. rotatable bonds :	8
Num. H-bond acceptors :	6.0
Num. H-bond donors :	2.0
Molar Refractivity :	158.89
TPSA :	102.93 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	No
P-gp substrate :	Yes
CYP1A2 inhibitor :	No
CYP2C19 inhibitor :	Yes
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	Yes
CYP3A4 inhibitor :	Yes
Log Kp (skin permeation) :	-6.83 cm/s

Lipophilicity

Log Po/w (iLOGP) :	4.74
Log Po/w (XLOGP3) :	3.74
Log Po/w (WLOGP) :	2.41
Log Po/w (MLOGP) :	1.71
Log Po/w (SILICOS-IT) :	1.86
Consensus Log Po/w :	2.89

Druglikeness

Lipinski :	1.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	0.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-5.14
Solubility :	0.00381 mg/ml ; 0.00000731 mol/l
Class :	Moderately soluble
Log S (Ali) :	-5.59
Solubility :	0.00133 mg/ml ; 0.00000255 mol/l
Class :	Moderately soluble
Log S (SILICOS-IT) :	-6.25
Solubility :	0.000296 mg/ml ; 0.000000568 mol/l
Class :	Poorly soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	0.0 alert
Leadlikeness :	3.0
Synthetic accessibility :	4.61

Safety of [ 755038-02-9 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P280-P305+P351+P338	UN#:	N/A
Hazard Statements:	H302	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 755038-02-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 755038-02-9 ]
Downstream synthetic route of [ 755038-02-9 ]

[ 755038-02-9 ] Synthesis Path-Upstream 1~9

1
[ 41838-46-4 ]
[ 755038-02-9 ]

Reference： [1] Patent: US2006/35903, 2006, A1, . Location in patent: Page/Page column 21
[2] ACS Medicinal Chemistry Letters, 2015, vol. 6, # 7, p. 764 - 769

2
[ 755039-55-5 ]
[ 876126-60-2 ]
[ 755038-02-9 ]

Reference： [1] ACS Medicinal Chemistry Letters, 2015, vol. 6, # 7, p. 764 - 769
[2] Patent: US2008/177066, 2008, A1, . Location in patent: Page/Page column 57; 60
[3] Patent: US2006/35902, 2006, A1, . Location in patent: Page/Page column 7

3
[ 41838-46-4 ]
[ 755039-56-6 ]
[ 755038-02-9 ]

Reference： [1] Angewandte Chemie - International Edition, 2011, vol. 50, # 40, p. 9378 - 9381
[2] Patent: WO2006/18182, 2006, A1, . Location in patent: Page/Page column 48; 76
[3] Patent: WO2006/18185, 2006, A2, . Location in patent: Page/Page column 48; 76
[4] Patent: US2004/176380, 2004, A1, . Location in patent: Page/Page column 15-16
[5] Patent: WO2004/76454, 2004, A1, . Location in patent: Page/Page column 49; 62
[6] Journal of Medicinal Chemistry, 2018, vol. 61, # 17, p. 7785 - 7795

4
[ 755039-53-3 ]
[ 755038-02-9 ]

Reference： [1] Angewandte Chemie - International Edition, 2011, vol. 50, # 40, p. 9378 - 9381
[2] ACS Medicinal Chemistry Letters, 2015, vol. 6, # 7, p. 764 - 769
[3] Journal of Medicinal Chemistry, 2018, vol. 61, # 17, p. 7785 - 7795

5
[ 755039-54-4 ]
[ 755038-02-9 ]

6
[ 755039-52-2 ]
[ 755038-02-9 ]

7
[ 5081-36-7 ]
[ 755038-02-9 ]

Reference： [1] ACS Medicinal Chemistry Letters, 2015, vol. 6, # 7, p. 764 - 769

8
[ 876126-59-9 ]
[ 755038-02-9 ]

Reference： [1] ACS Medicinal Chemistry Letters, 2015, vol. 6, # 7, p. 764 - 769

9
[ 755039-55-5 ]
[ 755038-02-9 ]

Reference： [1] Angewandte Chemie - International Edition, 2011, vol. 50, # 40, p. 9378 - 9381
[2] Journal of Medicinal Chemistry, 2018, vol. 61, # 17, p. 7785 - 7795

[ 755038-02-9 ] Synthesis Path-Downstream 1~15

1
[ 755038-02-9 ]
4-[[(7R)-8-cyclopentyl-7-ethyl-5-methyl-6-oxo-7H-pteridin-2-yl]amino]-3-methoxy-N-(1-methyl-4-piperidyl)benzamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
57%		BH3.SMe2 (0.2 niL, 5.0 M in THF, 1 nimol) was added to solution of 4-[[(7/?)-8-cyclopentyl- 7-ethyl-5-methyl-6-oxo-7H-pteridin-2-yl]amino]-3-methoxy-N-(l-methyl-4- piperidyl)benzamide (WO2004076454; 53 mg, 0.1 mmol) in THF (20 niL) and stirred at ambient temperature for 3 h under an atmosphere of nitrogen. After 3 hours, HCl (20 mL, concentrated aqueous) was added and the resulting solution was stirred at ambient temperature for 16 h. The HCl solution was then diluted with water (200 mL), and loaded onto an SCX-2 column. The SCX-2 column was then washed with water (50 mL), then MeOH (50 mL). The crude product was then eluted from the column with NH3 (50 mL, 7M in MeOH), and concentrated under reduced pressure. Purification by column chromatography (SiO2, eluent gradient 0-10% NH3 [7M in MeOH] in DCM) then by preparative HPLC (Xterra prep RPl 8, 19 x 100 mm column, eluting with a gradient composing of MeCN and a 1% solution ofNH3 in water), to give the title compound (29 mg, 57%) as a solid. 1H NMR (400 MHz, CDCl3): deltaH 0.94 (t, 3H), 1.50 - 1.83 (m, 10H), 1.91 - 1.95 (m, IH), 2.08 - 2.11 (m, 3H), 2.36 - 2.38 (m, 2H), 2.43 (s, 3H), 2.74 - 2.77 (m, IH), 2.80 (s, 3H), 3.01 (m, 2H,), 3.06 - 3.09 (m, IH), 3.36 - 3.39 (m, IH), 3.95 (s, 3H), 4.07 (m, IH), 4.88 (m, IH), 5.96 (d, IH), 7.21 - 7.23 (m, IH), 7.30 (s, IH), 7.37 (d, IH), 7.47 (s, IH), 8.53 (d, IH); MS m/z 508 [M+H]+.

Reference： [1]Patent: WO2007/135374,2007,A1 .Location in patent: Page/Page column 37

2
[ 41838-46-4 ]
[ 755038-02-9 ]

Yield	Reaction Conditions	Operation in experiment
		0.15 g of the compound Z3, 0.12 g TBTU, 0.12 mL DIPEA are dissolved in 5 mL dichloromethane and stirred for 30 minutes at 25 C. Then 50 mg 1-methyl-4-aminopiperidine are added and the mixture is stirred for a further 2.5 hours at 25 C. stirred. The solution is then extracted with water and then evaporated down. The residue is dissolved in warm ethyl acetate and crystallised using ether and petroleum ether. Yield: 0.025 g white crystals.

Reference： [1]Patent: US2006/35903,2006,A1 .Location in patent: Page/Page column 21
[2]ACS Medicinal Chemistry Letters,2015,vol. 6,p. 764 - 769

3
[ 755039-55-5 ]
[ 876126-60-2 ]
[ 755038-02-9 ]

Yield	Reaction Conditions	Operation in experiment
	With toluene-4-sulfonic acid; In Methyl isobutyl carbinol; for 5.0h;Heating / reflux;	Preparation of the Compound of Example No. 46 by Reacting 4 with 9; A suspension of 201 g (1.06 mol) para-toluenesulphonic acid-hydrate, 209 g (706 mmol) 9 and 183 g (695 mmol) 4 in 800 mL 2-methyl-4-pentanol is refluxed. 100 mL solvent are distilled off. The mixture is refluxed for 3 hours, 200 mL of 2-methyl-4-pentanol are added and 120 mL of solvent are distilled off. After 2 hours heating at reflux temperature a further 280 mL solvent are distilled off. The mixture is cooled to 100 C. and 1 L demineralised water and then 0.5 L ethyl acetate are added to the reaction solution. The organic phase is separated off and the aqueous phase is again washed with 0.5 L ethyl acetate. 1.5 L dichloromethane and 0.5 L ethyl acetate are added to the acidic aqueous phase. The pH value of the aqueous phase is adjusted to pH 9.2 with 260 mL of 6 normal sodium hydroxide solution. The aqueous phase is separated off and the organic phase is washed three times with in each case 1 L of 1 normal aqueous sodium hydrogen carbonate solution. The organic phase is dried over sodium sulphate, filtered and the solvent is evaporated down under reduced pressure. 406 g of crude product are obtained.The crude product is dissolved in 1.5 L ethyl acetate. At a temperature of 50-55 C. 2.5 L of methyl-tert.-butylether are added. The mixture is inoculated at 45 C. and stirred for 16 hours with cooling to ambient temperature. The suspension is stirred for 3.5 hours at 0-5 C. and the precipitate is suction filtered. The filter cake is washed again with methyl-tert.-butylether/ethyl acetate (2:1) and methyl-tert.-butylether. The product is dried at 50 C. in the vacuum drying cupboard. 236 g of crystalline compound of Example no. 46 are obtained as the anhydrate (I).
		A suspension of 201 g (1.06 mol) para-toluenesulphonic acid-hydrate, 209 g (706 mmol) 9 and 183 g (695 mmol) 4 in 800 mL 2-methyl-4-pentanol is refluxed. 100 mL solvent are distilled off. The mixture is refluxed for 3 hours, 200 mL of 2-methyl-4-pentanol are added and 120 mL of solvent are distilled off. After 2 hours heating at reflux temperature a further 280 mL solvent are distilled off. The mixture is cooled to 100 C. and 1 L demineralised water and then 0.5 L ethyl acetate are added to the reaction solution. The organic phase is separated off and the aqueous phase is again washed with 0.5 L ethyl acetate. 1.5 L dichloromethane and 0.5 L ethyl acetate are added to the acidic aqueous phase. The pH value of the aqueous phase is adjusted to pH 9.2 with 260 mL of 6 normal sodium hydroxide solution. The aqueous phase is separated off and the organic phase is washed three times with in each case 1 L of 1 normal aqueous sodium hydrogen carbonate solution. The organic phase is dried over sodium sulphate, filtered and the solvent is evaporated down under reduced pressure. 406 g crude product are obtained.

Reference： [1]ACS Medicinal Chemistry Letters,2015,vol. 6,p. 764 - 769
[2]Patent: US2008/177066,2008,A1 .Location in patent: Page/Page column 57; 60
[3]Patent: US2006/35902,2006,A1 .Location in patent: Page/Page column 7

4
[ 755038-02-9 ]
[ 876126-71-5 ]

Yield	Reaction Conditions	Operation in experiment
	In propan-1-ol; water; at 0 - 70℃; for 3h;Product distribution / selectivity;	46.5 g of the crystalline type I anhydrate described above are dissolved in 310 mL 1-propanol and filtered clear. The mixture is heated to 70 C. and 620 mL demineralised water are added. The solution is left cool to ambient temperature, cooled to 0-10 C. and seed crystals are added. The resulting suspension is stirred for 3 hours at 0-10 C. It is suction filtered and washed with cold 1-propanol/demineralised water (1:2) and demineralised water. The product is dried at 50 C. in the vacuum drying cupboard. 40.5 g crystalline product of the compound of formula (I) are obtained as the monohydrate. The crude product of the reaction described above may also be crystallised directly as the crystalline monohydrate from 1-propanol/demineralised water.

Reference： [1]Patent: US2006/35902,2006,A1 .Location in patent: Page/Page column 7

5
[ 41838-46-4 ]
[ 755039-56-6 ]
[ 755038-02-9 ]

Yield	Reaction Conditions	Operation in experiment
	With O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; N-ethyl-N,N-diisopropylamine; In dichloromethane; at 25℃; for 3h;Product distribution / selectivity;	0.15 g of the compound 23, 0.12 g TBTU, 0.12 mL DIPEA are dissolved in 5 mL dichloromethane and stirred for 30 minutes at 25C. Then 50 mg l-methyl-4- aminopiperidin are added and the mixture is stirred for a further 2.5 hours at 25C. The solution is then extracted with water and then evaporated down. The residue is dissolved in warm ethyl acetate and crystallised from ether and petroleum ether. Yield: 0.025 g of white crystals. M.p.: 203C as the base.; 0.15 g of the compound Z3, 0.12 g TBTU, 0.12 mL DIPEA are dissolved in 5 mL dichloromethane and stirred for 30 minutes at 250C. Then 50 mg l-methyl-4- aminopiperidin are added and the mixture is stirred for a further 2.5 hours at 25C. The solution is then extracted with water and then evaporated down. The residue is dissolved in warm ethyl acetate and crystallised from, ether and petroleum ether. Yield: 0.025 g of white crystals.
		0.15 g of the compound Z3, 0.12 g TBTU, 0.12 mL DIPEA were dissolved in 5 mL dichloromethane and stirred for 30 minutes at 25 C. Then 50 mg 1-methyl-4-aminopiperidin were added and the mixture was stirred for a further 2.5 hours at 25 C. The solution was then extracted with water and then evaporated down. The residue was dissolved in warm ethyl acetate and crystallised from ether and petroleum ether. Yield: 0.025 g of white crystals. M.p.: 203 C. as the base

Reference： [1]Angewandte Chemie - International Edition,2011,vol. 50,p. 9378 - 9381
[2]Patent: WO2006/18182,2006,A1 .Location in patent: Page/Page column 48; 76
[3]Patent: US2004/176380,2004,A1 .Location in patent: Page/Page column 15-16
[4]Patent: WO2004/76454,2004,A1 .Location in patent: Page/Page column 49; 62
[5]Journal of Medicinal Chemistry,2018,vol. 61,p. 7785 - 7795

7
[ 755039-53-3 ]
[ 755038-02-9 ]

Reference： [1]Angewandte Chemie - International Edition,2011,vol. 50,p. 9378 - 9381
[2]ACS Medicinal Chemistry Letters,2015,vol. 6,p. 764 - 769
[3]Journal of Medicinal Chemistry,2018,vol. 61,p. 7785 - 7795

8
[ 755039-54-4 ]
[ 755038-02-9 ]

9
[ 755039-55-5 ]
[ 755038-02-9 ]

Reference： [1]Angewandte Chemie - International Edition,2011,vol. 50,p. 9378 - 9381
[2]Journal of Medicinal Chemistry,2018,vol. 61,p. 7785 - 7795

10
[ 755039-52-2 ]
[ 755038-02-9 ]

11
[ 5081-36-7 ]
[ 755038-02-9 ]

Reference： [1]ACS Medicinal Chemistry Letters,2015,vol. 6,p. 764 - 769

12
[ 876126-59-9 ]
[ 755038-02-9 ]

Reference： [1]ACS Medicinal Chemistry Letters,2015,vol. 6,p. 764 - 769

13
[ 755039-56-6 ]
[ 755038-02-9 ]

Yield	Reaction Conditions	Operation in experiment
78 %	With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 25℃; Inert atmosphere;	6.1 Step 1. To a solution of 4-[[(7R)-8-cyclopentyl-7-ethyl-5-methyl-6-oxo-7H- pteridin-2-yl]amino]-3-rnethoxy-benzoic acid (0.5 g, 1.18 mmol, 1 equiv), l-methylpiperidin-4- amine (134.19 mg, 1.18 mmol, 1 equiv) in DMF (4 mL) was added DIEA (455.64 mg, 3.53 mmol, 614.07 uL, 3 equiv) and EDCI (337.92 mg, 1.76 mmol, 1.5 equiv), HOBt (238.18 mg, 1.76 mmol, 1.5 equiv). The mixture was stirred at 25 °C for 0.5 h. The residue was purified by /?/■3)-ACN]; B%: 32%-62%,llmin) to give compound 4-[[(7R)-8-cyclopentyl-7-ethyl-5- methyl-6-oxo-7H-pteridin-2-yl]amino]-3-methoxy-N-(l-methyl-4-piperidyl)benzamide (0.48 g, 78 % yield) was obtained as a white solid.

Reference： [1]Current Patent Assignee: HALDA THERAPEUTICS OPCO - WO2023/59582, 2023, A1 Location in patent: Paragraph 0327; 0352; 0402

14
[ 755038-02-9 ]
[ 4224-69-5 ]
[ 2922724-71-6 ]

Yield	Reaction Conditions	Operation in experiment
67 %	With potassium carbonate In N,N-dimethyl-formamide at 50℃; Inert atmosphere;	6.2 Step 2. To a solution of 4-[[(7R)-8-cyclopentyl-7-ethyl-5-methyl-6-oxo-7H- pteridin-2-yl]amino]-3-methoxy-N-(l-methyl-4-piperidyl)benzamide (250 mg, 479 umol, 1.0 equiv), methyl 2-(bromomethyl)prop-2-enoate (172 mg, 958 umol, 2.0 equiv) in DMF (1 mL) was added K2CO3 (265 mg, 1.92 mmol, 4.0 equiv). The mixture was stirred at 50 °C for 12 h. The residue was purified by />/■- HPLC (column: Waters Xbridge C18 15050mm10um; mobile phase: [water (NH4HCO3)-ACN]; B%: 31%-61%,llmin) to give compound methyl 2- [[N-[(7R)-8-cyclopentyl-7-ethyl-5-methyl-6-oxo-7H-pteridin-2-yl]-2-methoxy-4-[(l-methyl-4- piperidyl)carbamoyl] anilino]methyl]prop-2-enoate (0.2 g, 67 % yield) as a white solid.

Reference： [1]Current Patent Assignee: HALDA THERAPEUTICS OPCO - WO2023/59582, 2023, A1 Location in patent: Paragraph 0327; 0352; 0403

15
[ 755038-02-9 ]
[ 2922724-72-7 ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 2 steps 1: potassium carbonate / N,N-dimethyl-formamide / 12 h / 50 °C / Inert atmosphere 2: water; lithium hydroxide monohydrate / tetrahydrofuran / 0.5 h / 25 °C / Inert atmosphere

Reference： [1]Current Patent Assignee: HALDA THERAPEUTICS OPCO - WO2023/59582, 2023, A1

Same Skeleton Products

Related Products

Historical Records

Ghs Precautionary Statements

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]}	{[ getRatePrice(item.pr_usd, 1,1) ]}	Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]}	{[ item.pr_usastock ]}	Inquiry -	{[ item.pr_chinastock ]}	Inquiry -

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

[ CAS No. 755038-02-9 ] {[proInfo.proName]}

Quality Control of [ 755038-02-9 ]

Related Doc. of [ 755038-02-9 ]

Product Details of [ 755038-02-9 ]

Calculated chemistry of [ 755038-02-9 ]

Physicochemical Properties

Pharmacokinetics

Lipophilicity

Druglikeness

Water Solubility

Medicinal Chemistry

Safety of [ 755038-02-9 ]

Application In Synthesis of [ 755038-02-9 ]

[ 755038-02-9 ] Synthesis Path-Upstream 1~9

[ 755038-02-9 ] Synthesis Path-Downstream 1~15

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry